West Pharmaceutical Services (WST) EBITDA (2009 - 2026)

West Pharmaceutical Services has disclosed EBITDA across 18 years of filings, most recently posting $179.1 million for Q2 2026.

• In Q2 2026, EBITDA rose 16.53% year-over-year to $179.1 million; the TTM figure through Jun 2026 stood at $680.4 million (up 16.99% YoY), while the FY2025 annual figure was $584.9 million, up 2.63% from the prior year.
• EBITDA came in at $179.1 million for Q2 2026 at West Pharmaceutical Services, up from $177.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $228.4 million in Q2 2022 to a low of $107.0 million in Q1 2025.
• Average EBITDA over 5 years is $162.3 million, with a median of $161.1 million recorded in 2023.
• Year-over-year, EBITDA tumbled 30.85% in 2024 and surged 65.51% in 2026.
• Over 5 years, EBITDA stood at $129.7 million in 2022, then advanced by 24.06% to $160.9 million in 2023, then fell by 0.81% to $159.6 million in 2024, then retreated by 1.88% to $156.6 million in 2025, then gained by 14.37% to $179.1 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $179.1 million in Q2 2026, $177.1 million in Q1 2026, and $156.6 million in Q4 2025.